Page 9 - மருந்து நிறுவனம் வரையறுக்கப்பட்டவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Takeda Pharmaceutical Company Limited Takeda’s Growth and Emerging Markets Business Unit Aims to Deliver Double-Digit Revenue Growth Over Next Decade1 Friday, March 12, 2021 11:40AM IST (6:10AM GMT)   Aiming for Revenues of JPY 1 Trillion (approximately US$9 Billion2) by FY2030 Double-Digit Revenue Growth Expected to be Driven by a Balanced and Focused Geographic Presence, Portfolio of 14 Global Brands and Wave 1 Pipeline Assets Commitment to Patient Access to Medicines and Addressing Unmet Patient Needs in Emerging Markets Underpin Sustainable Growth   (TSE:4502/NYSE:TAK) (“Takeda”) today outlined its ambition for above-market, double-digit revenue growth of its Growth and Emerging Markets Business Unit (“GEM BU”). The revenue goal of JPY 1 trillion (approximately US$9 billion) by FY2030 represents more than doubling of current revenues in GEM BU. This potential growth will be primarily driven by a balanced geographical focus and targeted portfolio investments

United arab emiratesUnited statesBuenos airesDistrito federalHolly campbellKazumi kobayashiRicardo marekAsia pacificExchange commissionTakeda pharmaceutical company limitedTakeda pharmaceutical companyDigit revenue growth expectedFocused geographic presencePatient accessAddressing unmet patient needsEmerging markets underpin sustainable